Adobe (ADBE) Could Be 30% Undervalued After AI Growth And Strong Quarterly Results

Advertisement

Why Adobe’s Latest Swing in Sentiment Matters for Investors

Adobe (ADBE) has drawn fresh attention after a more than 6% share move, supported by stronger quarterly results, growing AI related offerings, firm subscription revenue, and ongoing share repurchases.

See our latest analysis for Adobe.

The latest 1 day share price return of 6.1% at US$225.11 follows a mixed stretch, with a 30 day share price return of 11.04% but a year to date decline of 32.46%. The 1 year total shareholder return has fallen 39.28% and longer term total shareholder returns are weaker, suggesting that enthusiasm around Adobe’s AI and subscription story is rebuilding from a lower base.

If the renewed interest in Adobe has you scanning for other potential opportunities around AI, this is a good moment to widen your search using the 65 profitable AI stocks that aren't just burning cash.

Adobe clearly has a sizeable, profitable business, but after a sharp one day jump and a weaker multi year return profile, the real issue now is whether the current share price still offers reasonable value.

Most Popular Narrative: 29.6% Undervalued

According to one of the most followed narratives on Adobe, a fair value of $319.96 is compared to the last close at $225.11, framing the stock as significantly undervalued in that view.

Before addressing AI risks, we must look at the underlying health of the business. Adobe’s financial profile remains elite:

Cash Flow Prowess: The company generated $10.32 billion in Free Cash Flow to Equity against $7.2 billion in Net Income. This surplus of cash over accounting earnings speaks to the exceptional quality of their revenue.

Read the complete narrative.

Want to understand why this fair value sits so far above Adobe’s share price? The narrative leans heavily on robust cash generation, resilient margins, and a disciplined growth path that is fully baked into a long term cash flow model.

Result: Fair Value of $319.96 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, investors still need to watch for two key risks: faster-than-expected competitive pressure in AI tools, and any sustained hit to Adobe’s high margins.

Find out about the key risks to this Adobe narrative.

Next Steps

If the mix of concern and optimism around Adobe has you thinking, this is a good time to move quickly and weigh the trade off between its risks and potential rewards for yourself by checking the 4 key rewards and 1 important warning sign.

Looking for more Adobe investment ideas?

If you are reassessing Adobe and want a clearer view of what else belongs on your watchlist, the right screeners can surface opportunities you might otherwise miss.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NasdaqGS:ADBE

Adobe

Operates as a technology company worldwide.

Undervalued with adequate balance sheet.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1157.5% undervalued
43 users have followed this narrative
2 users have commented on this narrative
6 users have liked this narrative
WE
WealthAP
NOVO B logo
WealthAP on Novo Nordisk ·

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

Fair Value:DKK 407.7721.4% undervalued
64 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
VA
ValueInvestingSubstack
ZTS logo
ValueInvestingSubstack on Zoetis ·

Zoetis down -50% over the past year

Fair Value:US$92.9218.9% undervalued
22 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
CE
CentryResearch
LEU logo
CentryResearch on Centrus Energy ·

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Fair Value:US$19013.7% undervalued
23 users have followed this narrative
0 users have commented on this narrative
10 users have liked this narrative

Updated Narratives

EU
European_Hidden_Gem_Stocks
RZLV logo
European_Hidden_Gem_Stocks on Rezolve AI ·

⚡ Two-Minute Drill: Rezolve AI - The AI That Doesn't Recommend Products. It Buys Them.

Fair Value:US$80.7897.2% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
EU
European_Hidden_Gem_Stocks
NET logo
European_Hidden_Gem_Stocks on Netcall ·

⚡ Two-Minute Drill: Netcall PLC - This £200M AI Stock Is Already Running the NHS

Fair Value:UK£2.1745.6% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
EU
European_Hidden_Gem_Stocks
FREEM logo
European_Hidden_Gem_Stocks on Freemelt Holding ·

Two-Minute Drill: Freemelt (STO: FREEM)

Fair Value:SEK 4.2662.7% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.919.1% undervalued
81 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.6% undervalued
71 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative
OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28026.1% undervalued
183 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0